+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Growth Opportunities in Liquid Biopsy, Diagnostics and Therapeutics in Multiple Disorders

  • PDF Icon

    Report

  • 66 Pages
  • September 2020
  • Region: Global
  • Frost & Sullivan
  • ID: 5232222

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) contains insights across various diagnostic tests, mostly liquid biopsy, AI, and genomic tests for cancer as well as for rheumatoid arthritis, metabolic diseases, and COVID-19 vaccine. Additionally, it covers therapies for amyotrophic lateral sclerosis and cancer, novel technologies such as teledentistry, novel insulin formulation, biosensing and regenerative medicine for hearing loss, probiotics for gut health of diabetics and CRISPR-based microbiome engineering technology.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.


Table of Contents

Innovations in Life Sciences, Health & Wellness


  • Personal Genome Diagnostics Inc., US
  • Growth Opportunities
  • Sysmex Inostics Gmbh, Germany
  • Growth Opportunities
  • Inivata Ltd., UK
  • Growth Opportunities
  • Freenome, US
  • Growth Opportunities
  • Guardant Health Inc., US
  • Growth Opportunities
  • Grail Inc., US
  • Growth Opportunities
  • Menarini Silicon Biosystems S.P.A., Italy
  • Growth Opportunities
  • Human Longevity Inc., US
  • Growth Opportunities
  • Epic Sciences, US
  • Growth Opportunities
  • Evelo Biosciences
  • Growth Opportunities
  • Pendulum Diagnostics, US
  • Growth Opportunities
  • Washington State University, US
  • Growth Opportunities
  • Thrive Earlier Detection Corp., US
  • Growth Opportunities
  • Delfi Diagnostics, US
  • Growth Opportunities
  • Lexent Bio (Foundation Medicine), US
  • Growth Opportunities
  • Base Genomics, UK
  • Growth Opportunities
  • Project Als, US
  • Growth Opportunities
  • Mouthwatch, US
  • Growth Opportunities
  • Skin Analytics, UK
  • Growth Opportunities
  • Stanford University, US
  • Growth Opportunities
  • Harvard Medical School, Usa
  • Growth Opportunities
  • Eligobioscience, France
  • Growth Opportunities
  • Rosa Biotech, UK
  • Growth Opportunities
  • University of Maryland School of Medicine, US
  • Growth Opportunities
  • University of Oxford, UK
  • Growth Opportunities
  • EPFL Institute of Bioengineering, Switzerland
  • Growth Opportunities
  • Key Contacts
  • Legal Disclaimer

 


Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Base Genomics, UK
  • Delfi Diagnostics, US
  • EPFL Institute of Bioengineering, Switzerland
  • Eligobioscience, France
  • Epic Sciences, US
  • Evelo Biosciences
  • Freenome, US
  • Grail Inc., US
  • Guardant Health Inc., US
  • Harvard Medical School, Usa
  • Human Longevity Inc., US
  • Inivata Ltd., UK
  • Lexent Bio (Foundation Medicine), US
  • Menarini Silicon Biosystems S.P.A., Italy
  • Mouthwatch, US
  • Pendulum Diagnostics, US
  • Personal Genome Diagnostics Inc., US
  • Project Als, US
  • Rosa Biotech, UK
  • Skin Analytics, UK
  • Stanford University, US
  • Sysmex Inostics Gmbh, Germany
  • Thrive Earlier Detection Corp., US
  • University of Maryland School of Medicine, US
  • University of Oxford, UK
  • Washington State University, US